London, UK; 17 June 2014: GW Pharmaceuticals a biopharmaceutical company focused on discovering, developing and commercializing novel therapeutics from its proprietary cannabinoid product platform, today announced physician reports of efficacy and safety data on 27 children and young adults with treatment-resistant epilepsy who have been treated with GW’s investigational cannabidiol (CBD) product candidate, Epidiolex®, for a period of 12 weeks. The treatment-resistant patients suffer from a range of epilepsies in which current anti-epileptic drugs have been unsuccessful in adequately controlling seizures, and included such severe forms of epilepsy as Dravet syndrome and Lennox-Gastaut syndrome. Uncontrolled data from two hospital sites in the United States that were generated under expanded access Investigational New Drug applications (INDs) authorized by the Food and Drug Administration (FDA) were made available to the Company.
Medical Cannabis News
A nearly 10-year long study conducted by researchers at California Pacific Medical Center’s Research Institute, and published this month by the British Journal of Pharmacology, has found that cannabinoids can combat breast cancer progression.
“The psychoactive cannabinoid Δ9 -tetrahydrocannabinol (THC) and the non-psychoactive cannabinoid cannabidiol (CBD) can both reduce cancer progression each through distinct antitumor pathways”, begins the study’s abstract. “Our goal was to discover a compound that could efficiently target both cannabinoid antitumor pathways.”
London, UK; 6 June 2014: GW Pharmaceuticals a biopharmaceutical company focused on discovering, developing and commercializing novel therapeutics from its proprietary cannabinoid product platform, today announced that the United States Food and Drug Administration (FDA) has granted Fast Track designation to GW’s investigational cannabidiol (CBD) product, Epidiolex®, in the treatment of Dravet syndrome, a rare and catastrophic treatment-resistant form of childhood epilepsy.
FDA's Fast Track program facilitates the development and review of drugs intended to treat serious conditions and fill an unmet medical need. A drug development program with Fast Track designation is afforded greater access to the FDA for the purpose of expediting the drug's development, review and potential approval to get important new drugs to the patient earlier.
Sao Paulo, Brazil: The administration of cannabidiol (CBD), a nonpsychotropic cannabinoid, controls sleep disorders in patients with Parkinson's disease (PD), according to a series of case summaries published in the Journal of Clinical Pharmacy and Therapeutics.
An international team of investigators from the University of Sao Paulo, Brazil and the University of Minnesota Medical School reported on the ingestion of CBD by four Parkinson's disease patients with REM sleep behavior disorder (RBD) - a condition characterized by nightmares and active behavior during dreaming.
A new study e-published ahead of print by Neuropsychopharmacology, the official publication of the American College of Neuropsychopharmacology, has determined that cannabinoids can help treat, or even prevent, the effects of PTSD.
Scientists from the Department of Psychology of the University of Haifa in Israel examined rat models suffering from shock-induced PTSD (post-traumatic stress disorder). The rats were each given an injection of either a cannabinoid receptor agonist (a substance that mimics the effects of cannabis) or a control placebo 2 hours after the shock.